Effectiveness of cimetidine as an adjunct to supplemental pancreatic enzymes in patients with cystic fibrosis.
The effectiveness and safety of the use of cimetidine as an adjunct to pancreatic enzymes was evaluated in eight patients with cystic fibrosis having pancreatic insufficiency. Cimetidine (300 mg, three times a day) was given for a 6-week period during which the patients demonstrated a significant weight gain (P < 0.05) and reduction of steatorrhea (P < 0.01). Data suggesting an early correction of the abnormal fatty acid composition of plasma lipids were observed. No side effects were apparent during the clinical trial. These results demonstrate the beneficial effects of the use of cimetidine in patients with cystic fibrosis and indicate the need for long-term clinical trials.
D000293:Adolescent; D000328:Adult; D001835:Body Weight / Q000187:drug effects; D002446:Celiac Disease / Q000188:drug therapy; D002648:Child; D002927:Cimetidine / Q000009:adverse effects / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D010188:Exocrine Pancreatic Insufficiency / Q000188:drug therapy*; D005227:Fatty Acids / Q000097:blood; D005260:Female; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D010184:Pancreatic Extracts / Q000627:therapeutic use*
D005227:Fatty Acids; D006146:Guanidines; D008055:Lipids; D010184:Pancreatic Extracts; D002927:Cimetidine